



PREPARATION AND EVALUATION OF SUSTAINED DOCETAXEL NANOCRYSTALS BY NANOPRECIPITATION METHOD

Prasad Garrepally^{*1}, Jagadeeshwar Kolguri¹, Vijaya Kumar Bontha¹, Laxmisamhitha Bontha¹

^{1,1*} Jangaon Institute of Pharmaceutical Sciences, Yeshwanthapur, Jangaon, Dist: Jangaon, Telangana State, 506167

*Corresponding Author Email: garrepallyprasad@gmail.com

ABSTRACT

The present study was aimed at preparing and evaluating nanocrystals of docetaxel (DTX). Total sixteen nanocrystal formulations were prepared by nanoprecipitation method using tween-80, egg lecithin and pladone C-12 as stabilizers and polylactic-co-glycolide (PLGA) as biodegradable polymer matrix in different molar ratios. Among those only four formulations were optimized based on their particle size and zeta potential values. Those optimized formulations were then characterized for their surface morphology, assay, in-vitro drug release profile, syringibility and injectability and dilution compatibility. The DTX nanocrystal formulations consist of rod and elongated cylindrical shaped crystals with a size ranging from 80 nm to 250 nm. The assay was found to be in the range of 99.562% to 103.25%. The zeta potential was in the range of -18.7 to -34.6 mV. In-vitro release data was plotted for cumulative % drug release as a function of time. In-vitro release study was analyzed using various mathematical models. Initially four formulations have shown burst release and later sustained drug release profile. F-13 (PLGA) formulation showed prolonged sustained drug release for 168 hr followed by F7 (egg lecithin) and F10 (PVP) for 96 hr and F2 (Tween80) for 72 hr. Based on the highest regression values (R), the best fit model for F2 and F13 were zero order, for F7 it was first order and for F10 it was peppas (super case II). All the formulations were freely passed through the lowest needle size i.e., 0.45*13 mm and they exhibited different levels of redispersibility at different time intervals.

KEY WORDS

Docetaxel, tween-80, egg lecithin, poly vinyl pyrrolidone, polylactic-co-glycolide, nanocrystals and in-vitro release.


INTRODUCTION

Among all newly discovered chemical entities about 40% drugs are lipophilic and fail to reach market due to their poor water solubility. Solubility the phenomenon of dissolution of solute in solvent to give a homogenous system, is one of the important parameters to achieve desired concentration of drug in systemic circulation for desired (anticipated) pharmacological response. Low aqueous solubility is the major problem encountered with formulation development of new chemical entities as well as for the generic development. The Biopharmaceutics Classification System (BCS) has been developed to provide a scientific approach to allow for the prediction of *in vivo* pharmacokinetic of oral

immediate release (IR) drug products. The importance of drug dissolution in the gastrointestinal tract and permeability across the gut wall barrier in the oral absorption process has been well known since 1960s. It provides very clear and easily applied rules in determining the rate-limiting factor in the gastrointestinal drug absorption process. Solubility also plays a major role for other dosage forms like parenteral formulations as well. Solubility is one of the important parameters to achieve desired concentration of drug in systemic circulation for achieving required pharmacological response. Poorly water-soluble drugs often require high doses in order to reach therapeutic plasma concentrations. Most of the drugs are either

weakly acidic or weakly basic having poor aqueous solubility. More than 40% NCEs (new chemical entities) developed in pharmaceutical industry are practically insoluble in water. These poorly water-soluble drugs having slow drug absorption leads to inadequate and variable bioavailability and gastrointestinal mucosal toxicity. Problem of solubility is a major challenge for formulation scientist. The improvement of drug solubility thereby its oral bioavailability remains one of the most challenging aspects of drug development process especially for oral-drug delivery system. There are numerous approaches available and reported in literature to enhance the solubility of poorly water-soluble drugs. The techniques are chosen on the basis of certain aspects such as properties of drug under consideration, nature of excipients to be selected, and nature of intended dosage form. Especially for class II (low solubility and high permeability) substances according to the BCS, the bioavailability may be enhanced by increasing the solubility and dissolution rate of the drug in the gastrointestinal fluids. The negative effect of compounds with low solubility include poor absorption and bioavailability, insufficient solubility for IV dosing, development challenges leading to increasing the development cost and time, burden shifted to burden shifted to patient (frequent high-dose administration). There are various techniques available to improve the solubility of hydrophobic drugs. Some traditional and novel approaches to improve the solubility are particle size reduction, solid dispersion, supercritical fluid technology, cryogenic technology, inclusion complex formation techniques and nanosuspensions. Nanosuspension is biphasic systems consisting of nano sized drug particles stabilized by surfactants for either oral and topical use or parenteral and pulmonary administration. The particle size distribution of the solid particles in nanosuspensions is

usually less than one micron with an average particle size ranging between 200 and 600 nm. There are various methods for preparation of nanosuspension include Media Milling (Nanocrystals), High Pressure Homogenization in water (Dissocubes), High Pressure Homogenization in nonaqueous media (Nanopure) and combination of Precipitation and High-Pressure Homogenization (Nanoedge). Drug nanocrystals are crystals with a size in the nanometer range, which means they are nanoparticles with a crystalline character. There are discussions about the definition of a nanoparticle, which means the size of a particle to be classified as a nanoparticle, depending on the discipline, eg, in colloid chemistry particles are only considered as nanoparticles when they are in size below 100 nm or even below 20 nm. Based on the size unit, in the pharmaceutical area nanoparticles should be defined as having a size between a few nanometers and 1000 nm ($\approx 1 \mu\text{m}$); microparticles therefore possess a size of 1–1000 μm . A further characteristic is that drug nanocrystals are composed of 100% drug; there is no carrier material as in polymeric nanoparticles. Dispersion of drug nanocrystals in liquid media leads to so called “nanosuspensions” (in contrast to “microsuspensions” or “macrosuspensions”). In general, the dispersed particles need to be stabilized, such as by surfactants or polymeric stabilizers. Dispersion media can be water, aqueous solutions or nonaqueous media (eg, liquid polyethylene glycol [PEG], oils). Properties of nanocrystals are size below 1 μm , 100% drug, no carrier, generally needed to be stabilized, crystalline or amorphous structure, increase of dissolution velocity, increase in saturation solubility, amorphous particle state offers advantages. The main reasons for the increased dissolution velocity by surface area enlargement and thus increased bioavailability.



Advantages of nanocrystal are increased rate of absorption, increased bioavailability, rapid effect, improved dose proportionality, reduction in required dose, applicability to all routes of administration, nanocrystals can be administered via oral routes such as tablets, capsules, sachets or powder; preferably in the form of a tablet. Nanosuspensions can also be administered via the intravenous route due to very small particle size, and in this way, bioavailability can reach 100 %, reduction in fed/fasted variability, rapid, simple and cheap formulation development, possibility of high amounts (30-40 %) of drug loading, increased reliability, sustained crystal structure-nanocrystal technology leads to an increase in dissolution rate depending on the increase in surface area obtained by reduction of the particle size of the active drug substance down to the nano size range preserving the crystal morphology of the drug, improved stability. They are stable systems because of the use of a stabilizer that prevents reaggregation of active drug substances during preparation. Suspension of drug nanocrystals in liquid can be stabilized by adding surface active substances or polymers. Applicability to all poorly soluble drugs because all these drugs could be directly disintegrated into nanometer-sized particles.

The purpose of current research work was to prepare and evaluate the sustained docetaxel nanocrystals by nanoprecipitation method for enhancement of solubility their by the bioavailability.

MATERIALS AND METHODS:

Docetaxel is a gift sample from Ningbo samreal chemicals Co., Ltd., China, Egg lecithin, Polysorbate-80 (tween-80), PVP (Plasdone C-12), Poly (Lactide-co-glycolide) acid, Purac biochem, Netherlands, Purac biochem, Netherlands, ethanol, Dichloromethane, Propylene glycol, N- Methyl Pyrrolide, n- Hexane, Oleyl alcohol, Sodium hydroxide and Potassium dihydrogen are from SD fine chemicals are AR grade. The preformulation studies with the lansoprazole obtained were performed using conventional and reported techniques. The UV-Visible spectrum, solubility, flow properties, drug crystallinity were determined.

PREFORMULATION STUDIES

Characterization of Docetaxel: The drug was stored in a well closed container and protected from light. It was characterized according to the USP monograph for description, solubility, pH of solution and melting point.

Drug solubility: Drug solubility in different solvents estimated by dissolving the drug in solvents at saturate level and mixed for 24hrs using shaker. After that the drug solution was filtered using 0.2µm filter and the drug concentration in the solution estimated by spectrophotometrically at 229 nm.

Drug excipient compatibility studies: Drug – stabilizer (PVP) and the pure drug were subjected to the Fourier transform infrared spectroscopy (FT- IR) in order to check the possible drug- stabilizer interactions.

Formulation of docetaxel parenteral nanocrystals by nano-precipitation method:

In this method, the drug was dissolved in solvent i.e., ethanol. After the drug, dissolved stabilizer solution was added. This solution was mixed using cyclomixer at 150 rpm. To this solution an Anti-solvent i.e., propylene glycol was added and mixed. The resulting formulation was kept aside for 24 hrs at room temperature. During optimization of a formula, the volume of solvent, anti-solvent and the concentration of stabilizer were considered in order to keep the formulation stable and that the final concentration of drug in the formulation is equivalent to the innovator product. The volume of solvent and anti-solvent was fixed in all the formulations by changing stabilizer concentration to a total volume of 2ml. In all the formulations, the drug and stabilizer were taken in the molar ratios. Docetaxel nanocrystals were prepared by using tween-80. The optimized nanocrystals of docetaxel were evaluated and characterized for particle size, zeta potential, in vitro drug release and shape by SEM. Docetaxel nanocrystals were prepared by using egg lecithin. The optimized nanocrystals of docetaxel were evaluated and characterized for particle size, zeta potential, in vitro drug release and shape by SEM. Docetaxel nanocrystals were prepared by using PVP. The optimized nanocrystals of docetaxel were evaluated and characterized for particle size, zeta potential, in vitro drug release and shape by SEM. Docetaxel nanocrystals were prepared by using tween-80 and PLGA. The optimized nanocrystals of docetaxel were evaluated and characterized for particle size, zeta potential, in vitro drug release and shape by SEM.

CHARACTERIZATION AND EVALUATION OF DOCETAXEL NANOCRYSTAL FORMULATIONS

Microscopic evaluation: Placed a drop of the formulation in the middle of a clean slide and place a cover slip. Then place the prepared slide onto the stage of the microscope. Observe the shape of crystals under microscope using 40x eyepiece and capture the images by using Motic image software.

Particle size and size distribution: The Particle size can be determined by measuring the random changes in the intensity of light scattered from a suspension. Small particles in suspension undergo random thermal motion known as Brownian motion. This random

motion is measured to calculate particle size. The average diameter and poly dispersity index (PDI) of the nanocrystals were determined by particle size analyzer (Horiba, nanopartica sz-100 series). 1mL of the sample was diluted to 10ml with water and 5ml of solution was transferred to cuvette and measured the particle size. Stokes-Einstein equation is used to calculate the particle size.

$$D_h = K_B T / 3\pi\eta Dt$$

Where:

D_h = the hydrodynamic diameter

Dt = the translational diffusion coefficient

k_B = Boltzmann's constant

T = temperature

η = dynamic viscosity

Zeta potential: Zeta potential is a measure of the charge on a particle surface in a specific liquid medium. This value of surface charge is useful for understanding and predicting interactions between particles in suspension. Zeta potential is measured using the technique of electrophoretic light scattering where particle motion is detected in an applied electric field. The charge on the surface of a particle influences the ionic environment in the region close to the particle surface. This ionic environment is typically described using a double layer model-the A zeta potential, measure the effect of electrostatic charges; this is the basic force that causes the repulse between adjacent particles. Net results are attraction or repulsion depends upon the magnitude of both forces. The thumb rule describes the relation between zeta potential determination responses of the suspension being tested, particularly hydrophobic colloids. Zeta potential was estimated using the zetasizer (Horiba, nanopartica SZ-100 series).

Zeta potentials is calculated based on Smoluchowski equation

$$\zeta = \frac{4\pi\eta}{\epsilon} * U * 300 * 300 * 1000$$

$$U = \alpha / [V/L]$$

Where

ζ = Zeta potential

η = Viscosity of solution

ϵ = Dielectric constant

U = Electrophoretic mobility

α = Speed of the particle (cm/sec)

V = Voltage and L = Distance of electrode

Shape and surface morphology: Shape and surface morphology of nanoparticles was done by Scanning Electron Microscopy. The three-dimensional information about macro (0.1-10mm) meso (1-100 μ m) and microstructure (10-1000nm), is often found within the same micrograph. SEM has been used to determine particle size distribution, surface topography, texture and to examine the morphology of fractured surface. Small volume of nanoparticulate suspension was placed on an electron microscope brass stub. The stubs were placed briefly in a drier and then coated with gold in an ion sputter. Pictures of nanoparticles were taken by random scanning of the stub. The shape and surface morphology of the nanoparticles was determined from the photomicrographs of each batch.

In vitro drug release study: Optimization of Dissolution

Media-Weighed quantities of drug was added to 300 ml of Phosphate Buffered Saline 7.4 and with PBS with different concentrations of Polysorbate 80 and stirred for 30 minutes and allowed to stand for 24 hours at room temperature. After 24 hour, the suspensions filtered and absorbance of the solution measured at absorption maxima.

Membrane diffusion drug release study: The *in vitro* release of formulations carried out by membrane diffusion technique using dialysis sack of Molecular weight cutoff 1000. Membrane was soaked in water for 30minutes to remove traces of preservative and tied to one end of the glass test tube which constituted donor compartment. 2ml of the formulation was transferred to donor compartment and placed into receptor compartment of 400 ml of Phosphate buffered saline Buffer pH with tween-80 maintained at a temperature of 37°C and rotated at 300rpm using a magnetic stir bar. At specified time points the samples were withdrawn buffer was removed and replaced with fresh buffer immediately after sampling. These samples were filtered through 0.45 μ m membrane filter and analyzed spectrophotometrically at 231 nm after suitable dilution if necessary, using appropriate blank.

Predicting mechanism of drug release: Various models were tested for explaining the kinetics of drug release.

To analyze the mechanism of the release rate kinetics of the dosage form, the obtained data fitted in to zero order, first order, Higuchi and Korsmeyer-Peppas release model, to study the drug release from the dosage form.

Zero order release rate kinetics: To study zero order release kinetics the release data are fitted to the following equation.

$$F = K_0 \cdot t$$

Where

F = the drug release

K_0 = the release rate constant and 't' is the release time

The plot of % drug release versus time is linear.

First order release rate kinetics: To study first - order release kinetics the release data are fitted to the following equation:

$$\log (100-F) = kt$$

The plot of log % drug release versus time is linear.

Higuchi's release model: To study the first -order release kinetics the release data are fitted to the following equation.

$$F = k_1 \cdot t^{1/2}$$

Where 'k₁' is the higuchi constant

In higuchi model, a plot of % release versus square root of time is linear.

Korsmeyer and peppas release model: To study the first-order release kinetics the release data are fitted to the following equation.

$$M_t / M_\infty = Kt^n$$

Where

M_t / M_∞ is the fraction of drug released

'k' is the release constant

't' is the release time and 'n' is the diffusion constant

If n= 0.89 the release is zero order

If n= 0.475 the release is best explained by Fickian diffusion and

If 'n' is 0.45<n<0.89 then the release through anomalous diffusion or non-fickian diffusion (swellable and Cylindrical matrix)

In this model, a plot of $\log (M_t / M_\infty)$ versus log (time) is linear

Table 1: The release data of optimized nanocrystal formulations were fitted to zero order, first order, Higuchi and korsmeyer- peppas model to study the kinetics of the drug release.

Model	Equation	Plot of graph	Parameters
Zero order	$F = K_0 \cdot t$	% of drug release versus time	K_0 - release rate constant
First order	$\log (100-F) = kt$	Log % drug release versus time	K – release rate constant
Higuchi release	$F = k_1 \cdot t^{1/2}$	% drug release versus square root time	K_1 -higuchi constant
Korsmeyer and peppas release	$M_t / M_\infty = Kt^n$	$\log (M_t / M_\infty)$	M_t / M_∞ - fraction of drug released constant n *exponent characterising diffusional mechanism

n *-The value of n determines the drug release mechanism

Table 02: Prediction of drug release mechanism

Diffusional exponent(n)	Drug release mechanism
<0.43	Fickian diffusion
0.43-0.85	Anomalous(non-fickian) transport
0.85-1	Case II transport
>1	Supercase II transport

RESULTS AND DISCUSSION


The solubility of pure drug in different solvents was carried out by dissolving the drug at saturated levels and it reveals that the drug is completely insoluble in water and propylene glycol, slightly soluble in poly ethylene glycol, soluble in dichloromethane, ethanol, n-methyl pyrrolidone and isopropyl alcohol. From the results, it was observed that highest solubility of docetaxel was observed in dichloromethane, followed by NMP, ethanol, isopropyl alcohol, polyethylene glycol, propylene glycol and very least was found in water. Among the solvents ethanol was selected by considering its safety compared to the other solvents,

solubility of drug and listed in FDA inactive ingredient guide at 49.7% usage for intravenous administration. From the I.R. spectral analysis it was found that I.R. spectrum of docetaxel with PVP 1:100 ratio showed all characteristic peaks in combination with no significant changes as shown in figure 1 and Table 3. The absorption spectrum of pure drug was scanned between 200-400 nm with 100, 50, 25, 12.5 $\mu\text{g/mL}$ concentration prepared in isopropyl alcohol. Docetaxel exhibits absorption peaks, at 229 nm and the other at 203 nm. The maximum absorbance is observed at 229 nm. Selection of the solvent and anti-solvent for formulation development is based on the solubility studies and published literature.

Table 03: Compatibility stretching of Docetaxel and Docetaxel +PVP

Functional Group	Docetaxel	Docetaxel +PVP
O-H bending	3378.16	3375.39
C-H Stretch	2984.39, 2931.59	2980.71, 2921.93
C=O stretch	1710.63	1711.85
C-H rock (alkane)	1365.62	1367.91
C-H rock (long chain) Alkanes	745	748.12
Aromatic C-H out of plane bending	708.53	709.61

Spectra Comparison



Result: OK



Correlation: 90.05 %

Threshold: 98.00 %

Sample: Docetaxel PVP.0

Compared with Reference: Docetaxel Drug05.0

Figure 01: IR spectra of Doectaxel and Physical mixture (Doectaxl +PVP)

Different shaped crystals were observed in all the formulations as given in the table. In case of F14, F15 and F16 as the polymer concentration increases, the clarity of formulations was decreased, because of the increase in viscosity due to its high molecular weight.

Upon standing the sediment was formed in those formulations so that they said to be physically unstable. From the above results, it was observed that the shape and size of the crystals was changed with the type and concentration of stabilizer.




Fig-6: MICROSCOPIC IMAGES OF TWEEN 80 FORMULATIONS




Fig.-7: MICROSCOPIC IMAGES OF EGG LECITHIN FORMULATIONS




Fig.-8: MICROSCOPIC IMAGES OF PVP FORMULATIONS




Fig.-9: MICROSCOPIC IMAGES OF PLGA FORMULATIONS

PARTICLE SIZE DISTRIBUTION

Particle size of all formulations was found in the nanometer range. The results of particle size data are shown in Table -5, 6, 7 and 8 in Fig.- 10,11,12.

Table-5: Experiment –II: Tween 80 formulations

Particle size	Molar Ratio			
	1:0.5[F1]	1:1[F2]	1:3[F3]	1:6[F4]
D ₁₀	194.6	118.1	52.2	120.3
D ₅₀	268	144.2	190	137.5
D ₉₀	257.4	178.7	173	142.4
Mean Diameter	240nm	142.9nm	138.4	133.4nm
PDI	0.562	0.512	0.852	0.587




Fig. 10: Tween 80 Formulations Particle size (nm) and Polydispersity index

CONCLUSION:

All the formulations consist of nanosized particles, the average size and polydispersity index of nanocrystals were given in the table. The size of docetaxel nanocrystals in this study were ranged between 133.4 to 240 ±22.2 nm. the particle size of four molar ratios found to be in the following order: F1 [1:0.5] > F2 [1:1] >

F3 [1:3] > F4 [1:6]. From f1 to f2 there was a greater decrease in particle size but in case of f3 and f4 it was a slight decrease in particle size and the size was almost nearer to the f2 formulation. From this observation, it can be concluded that after 1:1 molar ratio, upon increasing the tween80 concentration there was no greater decrease in the particle size so, there was no use of further increasing stabilizer concentration.

Table-6: Experiment –III: Egg lecithin formulations

Particle size of all formulations was found in the nanometer range. The results of particle size data are shown in Table-6.

Particle size	Molar ratios			
	1:0.5[F5]	1:1[F6]	1:3[F7]	1:6[F8]
D ₁₀	256	255.1	154.2	595.6
D ₅₀	473.2	287.8	172	663.3
D ₉₀	310.3	326.4	198.2	311.3
Mean Diameter	346.5	289.1nm	174.8nm	523.4nm
PDI	0.756	0.542	0.489	0.655




Fig. 11: Egg lecithin Formulations Particle size (nm) and Polydispersity index

Conclusion:

All the formulations consist of nanosized particles, the average size and polydispersity index of nanocrystals were given in the table. The size of docetaxel nanocrystals in this study were ranged between 523.4 to 174.8±24.3nm. the particle size of four molar ratios found to be in the following order: F8 [1:6] > F5 [1:0.5] > F6 [1:1] > F7 [1:3]. From f5 to f7 there was a greater decrease in particle size but in case of f6, the particle

size was again increased this is because, we believe our nanocrystals are in a meta-stable state stabilized by surface adsorbed egg lecithin surfactant. At low concentration of egg lecithin, monomers bind with high affinity to the crystal surface. At high concentration, monomers aggregated and bind to surface with low affinity, there is also micelle formation competing for surface adsorption. Thus, the lowest size was found in the f7 i.e., 174.8 ±24.3nm.

Table-7: Experiment –IV: PVP formulations

Particle size of all formulations was found in the nanometer range. The results of particle size data are shown in Table-7.

Particle size	Molar ratio			
	1:0.5[F9]	1:1[F10]	1:3[F11]	1:6[F12]
D ₁₀	269.5	106.9	133.8	121.7
D ₅₀	274.2	166.5	171.6	151.3
D ₉₀	544.4	270.1	154.2	160.5
Mean Diameter	362.7nm	161nm	153.2nm	144.5nm
PDI	0.785	0.593	0.469	0.454




Fig. 12: PVP Formulations Particle size (nm) and Polydispersity index

Conclusion: All the formulations consists of nanosized particles, the average size and polydispersity index of nanocrystals were given in the table. The size of docetaxel nanocrystals in this study were ranged between 362.7 to 144.5±62.9 nm. the particle size of four molar ratios found to be in the following order: F9 [1:0.5] > F10 [1:1] > F11 [1:3] > F12 [1:6]. From f9 to f10 there was a greater decrease in particle size but in case

of f11 and f12 it was a slight decrease in particle size and the size was almost nearer to the f10 formulation. From this observation, it can be concluded that after 1:1 molar ratio, upon increasing the PVP concentration there was no greater decrease in the particle size so, there was no use of further increasing stabilizer concentration.

Table-8: Experiment –V: Tween 80 and PLGA formulations

Particle size of the formulation was found in the nanometer range. The results of particle size data are shown in Table-8.

Particle size	Molar ratio
	1:1:0.001 [F13]
D ₁₀	29.3
D ₅₀	58.6
D ₉₀	170.9
Mean Diameter	81.0nm
PDI	0.726


Conclusion: The particle size and poly dispersity index of PLGA nanocrystals was given in the table. In case of tween 80- 1:1 formulation the particle size was found to be 142.9 nm. This size was still reduced to 81±61.2 nm with the addition PLGA to the formulation this is due to, PLGA provides the additional effect to the surfactant by reducing the particle reaggregation by impating the viscosity to the formulation.

3. ZETAPOTENTIAL

Zeta potential of all formulations was found in the in the range of -18.17 to - 34.60 mV. The results of Zeta potential data are shown in Table-9 in Fig.13.

Table-9: Zeta potential Data for All formulations

Experiment number	Formulation code	Molar ratio	zetapotential
II	F1	1:0.5	-30.2
	F2	1:1	-31.8
	F3	1:3	-24.5
	F4	1:6	-18.7
	F5	1:0.5	-31.5
III	F6	1:1	-32.6
	F7	1:3	-34.6
	F8	1:6	-28.3
	F9	1:0.5	-19.8
IV	F10	1:1	-29.4
	F11	1:3	-22.6
	F12	1:6	-23.8
V	F13	1:1:0.001	-32.4


Fig. 13: Zeta Potential for All formulations

Conclusion: The stability study of the nanocrystals was evaluated by measuring the zeta potential of the nanocrystals by the zeta meter. The results are evaluated in Table. Zeta potential of all formulated nanocrystals was in the range of -18.17 to - 34.60

mV. which indicates moderate stability with no agglomeration.

Based on the particle size, polydispersity index and zeta potential values the four formulations from total of thirteen formulations were selected as optimized formulations.

INVITRO RELEASE PROFILE OF DOCETAXEL NANOCRYSTAL FORMULATIONS FOR PARENTERAL ADMINISTRATION:

1.1. Optimization of dissolution media

Parameter	Qty of drug	Volume of Buffer	Abs	Concentration [mg/mL]
PBS 7.4	20mg	50mL	0.02	0.01
PBS 7.4+ 1% Tween 80	20mg	50mL	0.11	0.03
PBS 7.4 + 2% Tween 80	20mg	50mL	0.195	0.08
PBS 7.4+ 4% Tween 80	20mg	50mL	0.42	0.14
PBS 7.4 + 6% Tween 80	20mg	50mL	0.75	0.25

The saturation solubility of Docetaxel in PBS7.4 with 6% Tween 80 found to be 0.25 mg/mL, thus 600mL of Buffer will provide the required sink condition of ≥ 3 .

1.2. Release Profile and Kinetics

Table -10: Zero order release profile of optimized formulations:

Time in hours	Cumulative % drug release			
	Tween 80[F2]	Egg lecithin[F7]	PVP[F10]	PLGA[F13]
0	0	0	0	0
24	31.216	43.138	47.665	5.82
48	50.158	59.562	64.766	16.252
72	74.523	70.454	81.216	29.684
96	100	84.312	90.213	51.799
120	--	--	--	66.753
144	--	--	--	80.408
168	--	--	--	97.987




Fig. 14: *Invitro* release profile of Zero order release kinetics
Table -11: First order release profile of optimized formulations:

Time in hours	Log Cumulative % drug remain release			
	Tween 80[F2]	Egg lecithin[F7]	PVP[F10]	PLGA[F13]
0	2	2	2	2
24	1.837487	1.754822131	1.718792	1.973959
48	1.697595	1.606789668	1.546962	1.922974
72	1.406148	1.470498693	1.273788	1.847054
96	--	1.1955675	0.990649	1.683056
120	--	--	--	1.521752
144	--	--	--	1.292079
168	--	--	--	0.303843




Fig. 15: *Invitro* release profile of First order release kinetics

Table no. 12: Higuchi release profile of optimized formulations:

vT	Cumulative % drug release			
	Tween 80[F2]	Egg lecithin[F7]	PVP[F10]	PLGA[F13]
0	0	0	0	0
4.898979	31.216	43.138	47.665	5.82
6.928203	50.158	59.562	64.766	16.252
8.485281	74.523	70.454	81.216	29.684
9.797959	100	84.312	90.213	51.799
10.95445	--	--	--	66.753
12.00	--	--	--	80.408
12.96148	--	--	--	97.987




Fig. 16: *Invitro* release profile of Higuchi release kinetics

Table -13: Korsmeyer-peppas release profile of optimized formulations:

Log time	Log Cumulative % drug release			
	Tween 80[F2]	Egg lecithin[F7]	PVP[F10]	PLGA[F13]
0	0	0	0	0
1.380211	1.494377	1.63486001	1.6781996	0.764923
1.681241	1.70034	1.77496927	1.81134708	1.210907
1.857332	1.87229	1.84790566	1.9096416	1.472522
1.982271	2	1.92588939	1.95526912	1.714321
2.079181	--	--	--	1.824471
2.158362	--	--	--	1.905299
2.225309	--	--	--	1.991168




Fig.17: *Invitro* release profile of Korsmeyer-peppas release kinetics

REGRESSION COEFFICIENT AND DIFFUSION COEFFICIENT VALUES OBSERVED IN VARIOUS KINETIC MODELS FOR FOUR FORMULATIONS OF DOCETAXEL NANOCRYSTALS:

FORMULATION	ZERO ORDER	FIRST ORDER	HIGUCHI	KORSMEYER PEPPAS	
	R ²	R ²	R ²	R ²	n
Tween80[F2]	0.993	0.970	0.924	0.996	1.020
Egg lecithin[F7]	0.849	0.984	0.998	0.975	1.031
PVP[F10]	0.836	0.994	0.998	0.973	1.055
PLGA[F13]	0.968	0.735	0.767	0.929	0.827

In-vitro release data obtained for optimized formulations F2, F7, F9 and F13 are tabulated in Table no. respectively with their corresponding plots. Cumulative percentage drug released for F2 after 96 hours was more i.e., 100%, followed by F10 was 90.213% and for F7 was 84.312%. Where as in case of F13 the cumulative percentage drug released after 96 hours was only 51.799 and reached 97.987% after 168 hours. It was evident that the drug release from the F13 formulation decreased compared with the other three formulations. It was suggesting that the presence of polymer sustained the drug release. The formulations F2, F7 and F9 showed a biphasic release with initial burst effect. The mechanism for the burst release can be attributed to the sudden exposure of nanocrystal surface to the PBS. By this one can conclude that the dissolution rate was enhanced by nanocrystal formulations. But the presence of polymer layer around the particle avoid the sudden exposure of particle surface to the surrounding medium there by expect a slow drug release. Calculated regression co-efficient and diffusion co-efficient values for four formulations were tabulated in Table. Plots of zero order, first order, Higuchi and Peppas's were depicted in Fig. These values were compared with each other for model and drug equation. Based on highest regression [r²] values, the best-fit model for F2 and F13 was zero order and for F7 and F10 was Higuchi diffusion model. All the formulations were then fitted into Korsmeyer-peppas model and n values were reported. For F2, F7 and F10 it was >1 indicates Supercase-II transport and for F13 it was <0.89 indicates non-fickian diffusion.

CONCLUSION:

Cancer is the end product of a multi-step process that occurs over many years. "Cancer refers to any one of a

large number of diseases characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue". The Drug delivery remains a challenge in management of cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulation for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent the damage to normal tissues and prevent drug resistance. Nanoparticles have been used *in vivo* to protect the drug entity in the systemic circulation, restrict access of the drug to the chosen sites and to deliver the drug at a controlled and sustained rate to the site of action. Various polymers have been used in the formulation of nanoparticles for drug delivery to increase therapeutic benefit while minimizing side effects. Recently there has been immense interest in nanocrystal technology. nanocrystallization is a technique to produce crystalline particles of poorly soluble drugs in the nanometer range (i.e., nanocrystals). Due to the size and, thus, the high surface area to volume ratio, nanocrystals can increase the saturation solubility of a drug and the dissolution rate of drug particles. Nanocrystals have gained increasing interest in the pharmaceutical industry because of the simple structures, compositions and controlled release affords less frequent administration, thereby increasing patient compliance, reducing discomfort, protecting the therapeutic compound and maintaining constant blood levels of the drug within body. Docetaxel is presently marketed as TAXOTERE.RTM. injection concentrate by Aventis Pharmaceutical (Bridgewater, N.J.). Because of poor water solubility docetaxel is given in a vehicle containing high concentration of tween 80 & the

injection need to be diluted with 13 % ethanol in water for injection. The presence of tween 80 & ethanol cause severe adverse effects like several hypersensitivity reactions also incompatibility with common PVC intravenous administration sets. Hypersensitivity symptoms associated with docetaxel include hypotension, bronchospasm and generalized rash / erythema in addition to bone marrow suppression, peripheral neurotoxicity and mucositis. Nanocrystals have been used *in vivo* to protect the drug entity in the systemic circulation, restrict access of the drug to the chosen sites and to deliver the drug at a controlled and sustained rate to the site of action. Various polymers have been used in the formulation of nanocrystals for drug delivery research to increase therapeutic benefit, while minimizing side effects. Most of the nanocrystals are taken up from blood by macrophages of reticuloendothelial system; therefore, nanocrystals can provide an effective strategy in controlled drug delivery for concentration of docetaxel in liver, lungs, spleen, kidney and small intestine. Docetaxel nanocrystals were prepared by using nanoprecipitation method using different types of stabilizers and polymers. Total sixteen formulations were prepared and labeled as F1, F2, F3....F16 by changing concentration of stabilizers and polymer. The stabilizers used are tween 80, Egg lecithin and PVP and the polymer used is PLGA. The pre-formulation studies were performed with pure drug and excipients and the prepared formulations were evaluated for parameters like particle size, zeta potential, scanning electron microscopy, assay, *invitro* drug release, dilution compatibility, syringeability and injectability, stability testing and others. Preformulation studies revealed that the docetaxel and PVP were compatible without any significant changes in the chemical nature of the docetaxel. Based on the particle size distribution, PDI and Zeta potential values four formulations were selected as best formulations and those four formulations were evaluated for further parameters. Particle size of the Docetaxel nanocrystals revealed that the all formulations were found in nanometer range and the Zeta potential was in the acceptable limit. The amount of % drug content in docetaxel nanocrystals was found to be 100%, 102.12%, 99.562% and 103.25% respectively for formulations F-2, F-7, F-10 & F-13. All the formulations were stable up to

8 hours upon dilution and all formulations were passed freely from five different needle sizes. *In-vitro* release study was analyzed using various mathematical models. Cumulative percentage drug released for F2 after 96 hours was more i.e., 100%, followed by F10 was 90.213% and for F7 was 84.312%. Where as in case of F13 the cumulative percentage drug released after 96 hours was only 51.799 and reached 97.987% after 168 hours. It was evident that the drug release from the F13 formulation decreased compared with the other three formulations. It was suggesting that the presence of polymer sustained the drug release. Based on highest regression [r^2] values, the best-fit model for F2 and F13 was zero order and for F7 and F10 was Higuchi diffusion model. All the formulations were then fitted into Korsmeyer-Peppas model and n values were reported. For F2, F7 and F10 it was >1 indicates supercase-II transport and for F13 it was <0.89 indicates Non-Fickian diffusion. Parenteral nanocrystal optimized formulations were kept at accelerated stability. It was observed that there was no change in the physical appearance of the formulation. The physical appearance of the formulation remained clear and colorless solution at the end of stability. pH of the formulation remained unchanged during stability.

REFERENCES

1. Formulation and evaluation of liposomal drug delivery system for an anticancer drug and the Study the effect of various stabilizers based on physicochemical and *in vitro* characterization. Ganesh g. N. K, gowthamarajan k, suresh kumar r, Senthil v, jawahar n, venkatesh n, manjusha. P, department of pharmaceuticals, j. S. S. College of pharmacy, Tamilnadu, india. IJPRD, 2011; Vol 3(3): May 2011 (27 -37).
2. Understanding the structure and stability of paclitaxel nanocrystals. Jiexin Deng, Leaf Huang, Feng Liu. International Journal of Pharmaceutics 390 (2010) 242–249.
3. Docetaxel-loaded solid lipid nanoparticles: Preparation, characterization, *in vitro*, and *in vivo* evaluations. Navid Mosallaei, Mahmoud Reza Jaafari, Mohammad Yahya Hanafi-Bojd, Shiva Golmohammadzadeh, Bizhan Malaekhe-Nikouei, American Pharmacists Association J Pharm Sci 102:1994–2004, 2013.
4. Preparation And Characterization Of Simvastatin Nanosuspension By Homogenization Method, Athul P.V. Nandha College Of Pharmacy And Research Institute,

- Erode 52, India. International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN: 0974-4304, Vol.5, No.1, pp 193-197, Jan-Mar 2013.
5. Kinetic modeling on drug release from controlled drug delivery systems, Suvakanta dash¹, padala narasimha murthy, lilakanta nath and prasanta chowdhury girijananda chowdhury institute of pharmaceutical science, Azara, hathkhowapara, nh-37, guwahati, assam, 781 017 india. Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 67 No. 3 pp. 217 n 23, 2010.
6. Evaluation of drug release kinetics from ibuprofen matrix tablets using hpmc M.Harris shoab, jaweria tazeen, hamid a. Merchant And rabia ismail yousuf. Department of pharmaceuticals, faculty of pharmacy, university of karachi, Karachi-75270, Pakistan. Pak. J. Pharm. Sci., 2006, Vol.19 (2), 119-124.
7. Nanoparticles – A Review, VJ Mohanraj¹ and Y Chen, Orchid Chemicals & Pharmaceuticals Limited, Chennai, India School of Pharmacy, Curtin University of Technology, Perth, Australia. Tropical Journal of Pharmaceutical Research, June 2006; 5 (1): 561-573.
8. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody, Petra Kocbek, Natasa Obermajer, Mateja Cegnar, Janko Kos, Julijana Kristl.
9. Drug nanocrystals: A novel formulation approach for poorly Soluble drugs, Suman kotteboinaa¹, v s r chandrasekhar. P, balaji. S, department of pharmaceuticals, bapatla college of pharmacy, bapatla, guntur dist, Andhra pradesh, india – 522101. International Journal of PharmTech Research CODEN(USA): IJPRIF ISSN : 0974-4304 Vol.1, No.3, pp 682-694 , July-Sept 2009.
10. A review on drug nanocrystal a carrier free drug delivery, patel.anita p, patel j.k., patel kishubu s., Nootan Pharmacy College, Visnagar-384315, Gujarat, India.IJRAP 2011, 2(2) 448-458.
11. Amidon GL, Lennemas H, Shah VP, Crison JR. A Theoretical basis for biopharmaceutic drug classification: the correlation of the *in vitro* drug product dissolution and *in vivo* bioavailability. Pharm Res. 1995; 12: 413-420.
12. Lennernas H, Abrahamson B. The use of the biopharmaceutics classification in drug discovery and development: Current status and future extension. In drug bioavailability, estimation of solubility, permeability, absorption and bioavailability. J Pharm Pharmacol. 2005; 57:273-285.
13. Mohanraj VJ, Chen Y. Nanoparticles - A Review. Trop J Pharm Res 2006;5(1):561-3.
14. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J control release 2003; 86:33-48.
15. Magharla DD, Rajagopalan R, Devrajan S, Rajadas J, Vamsadhara C. Biodegradation and biocompatibility of contraceptive-steroid-loaded poly (DL- lactide-co-glycolide) injectable microspheres: *in vitro* and *in vivo* study. Contraception. 2006; 74:148-56.
16. Berklund C, King M, Cox A, Kim K, Pack DW. Precise control of PLG microspheres size provides enhanced control of drug release rate. J Control Release. 2002; 82:137-47.
17. Preparation and antitumor study of camptothecin nanocrystals, Hua Zhanga, Christin P. Hollis, Qiang Zhanga, Tonglei Li, International Journal of Pharmaceutics 415 (2011) 293–300.
18. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions, Xiaohui Pua, Jin Suna, YanWang, International Journal of Pharmaceutics 379 (2009) 167–173.
19. Zhang, X., Xia, Q., Gu, N., 2006b. Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug Dev. Ind. Pharm. 32, 857–863.
20. Muller, R.H., Peters, K., Becker, R., Kruss, B., 1995a. Nanosuspensions—a novel formulation for the *i.v.* administration of poorly soluble drugs. In: 7th Int. Conf. on Pharm. Technol. (APV:APGI), Budapest, pp. 491–492.
21. Peters, K., Leitzke, S., Diederichs, J.E., Borner, K., Hahn, H., Müller, R.H., Ehlers, S., 2000. Preparation of clofazamine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in *Mycobacterium avium* infection. J. Antimicrob. Chem. 45, 77–83.
22. Phanchaxari Dandagi. M., Sumit Kaushik., Shaktish Telsang., Enhancement of solubility and dissolution property of Griseofulvin by nanocrystallization, Int. J. Drug Dev. & Res, 3(2), 2010, 180-191.
23. Suvakanta Dash¹, Padala Narasimha Murthy., Lilakanta Nath., Prasanta Chowdhury., Kinetic modeling on drug release from controlled drug delivery systems, Acta Poloniae Pharmaceutica-Drug Research, 67(3), 2010, 217-223.
24. Yuan Gao., Jianjun Zhang., Huixia Lv., Kun Jiang., Enhanced bioavailability after oral and pulmonary administration of Baicalein nanocrystal, Int. J. Pharm, 420, 2011, 180-188.
25. Dianrui Zhang., Guangpu Liu., Yang Jia., Dandan Zheng., Yue Liu., Cunxian Duan., Leijiao Jia., Qiang Zhang., Hongxiang Lou., Comparison of different methods for preparation of a stable riccardin D formulation via nanotechnology, Int. J. Pharm, 422, 2012, 516-522.
26. Peng Liu., Xinyu Rong., Johanna Laru., Bert van Veen., Juha Kiesvaara., Jouni Hirvonen., Timo Laaksonen., Leena Peltonen., Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling, Int. J. Pharm, 411, 2011, 215-222.

27. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. *J Pharm Pharmacol.* 2004;56 (7):827–40.
28. Li X, Gu L, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. *Drug Dev Ind Pharm.* 2009;35(7):827–33.
29. Mishra PR, Al Shaal L, Muller RH, Keck CM. Production and characterization of Hesperetin nanosuspensions for dermal delivery. *Int J Pharm.* 2009;371(1–2):182–9.
30. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. *Adv Drug Deliv Rev.* 2001;47 (1):3–19.
31. Muller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. *Int J Pharm.* 1998; 160:229–37.
32. Wang L, Cui FD, Sunada H. Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method. *Chem Pharm Bull.* 2006;54(1):37–43. 1142 Quan et al.
33. Docetaxel-loaded liposomes: preparation, pH sensitivity, Pharmacokinetics, and tissue distribution, Hong zhang, Rui-ying L, *Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)*, Received Mar. 27, 2012; Revision accepted Nov. 11, 2012; Crosschecked Nov. 14, 2012.
34. Baker, J., Ajani, J., Scotté, F., Winther, D., Martin, M., Aapro, M.S., von Minckwitz, G., 2009. Docetaxel-related side effects and their management. *Eur. J. Oncol. Nurs.*,13(1):49-59. [doi: 10.1016/j.ejon.2008.10.003].
35. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel, Maria Laura Immordino, Paola Brusa, *Journal of Controlled Release* 91 (2003) 417-429.
36. T.Musumeci, C.A. Ventura, I. Giannone, B.Ruozzi, L.Montenegro, R.Pignatello, G.Puglisi (2006). PLA/PLGANanoparticles for sustained release of docetaxel, *International Journal of pharmaceutics* 325,172-179.

***Corresponding Author:**

Prasad Garrepally*

Email: garrepallyprasad@gmail.com